Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Short Course Zinc Therapy (5 vs 10 d) With 20 mg Elemental Zinc Daily in the Treatment of Acute Diarrhoea: A Double-blind Individually Randomized Controlled Community Trial.
Brief Summary: Diarrhoea continues to be a major cause of mortality and morbidity in young children especially in many developing countries. Although the mortality burden of diarrhoea has substantially reduced, the morbidity pattern remained almost unchanged. Recent randomized controlled supplementation trials in developing countries have consistently shown that zinc has the potential to reduce the duration of diarrhoea as well as has preventive effect on childhood diarhroea in subsequent months. Currently, international health agencies recommend zinc as an important adjunct therapy to treat diarrhoea in developing countries where zinc deficiency is highly prevalent and diet is poor in zinc.

The recommendation is to provide 20 mg elemental zinc daily for 10 days during each episode of diarrhoea.

This study aims at evaluating the relative efficacy of two length of 20 mg zinc therapy (5 vs 10 days) during acute diarrhoea in a rural community in a community-based individually randomized placebo-controlled trial with 20 mg zinc daily and will be conducted in seven villages in the ICDDR,B Matlab study area.

The study will require 2050 acute dirrhoeal episodes to be treated who will be randomly allocated to one of the two treatment schedules (20 mg of zinc daily for 5 or 10 days). Children who will be allocated to the shorter duration therapy will receive placebo for the remaining days to complete 10-day treatment. Female Field Workers (FFWs) will conduct diarrhoea surveillance and administer zinc daily at home. Data will be analyzed using appropriate statistical procedure.

Findings of this study will be immensely valuable for deciding recommendation for the duration of zinc therapy in the management of acute diarrhoea in young children and will have profound programmatic and policy implications for scaling up zinc intervention in the community.


Options:
A: Intervention Type: DRUG; Name: ZINC; Assigned to Arm(s): N/A
B: Arm Label: Daily preventive Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Daily preventive Zn; placebo treatment | Arm Label: Therapeutic Zn; daily placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Therapeutic Zn; daily placebo | Arm Label: Intermittent Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Intermittent Zn; placebo treatment | Arm Label: Surveillance control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Surveillance control group | Arm Label: Non-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Daily preventive Zn; placebo treatment; Assigned to Arm(s): Daily preventive Zn; placebo treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Therapeutic Zn; daily placebo; Assigned to Arm(s): Therapeutic Zn; daily placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Intermittent Zn; placebo treatment; Assigned to Arm(s): Intermittent Zn; placebo treatment | Intervention Type: OTHER; Name: Surveillance control group; Assigned to Arm(s): Surveillance control group
C: Intervention Type: DRUG; Name: Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A

Answer: A